Covista Inc. (CVSA) · Aug 6, 2026 · Company update

Strong Q4 beat and FY26 outperformance, but FY27 targets reset lower

Strong Q4 beat and FY26 outperformance, but FY27 targets reset lower

The quarter beat the market’s immediate expectation by a meaningful margin. Adjusted EPS was $2.09 versus a published consensus of approximately $1.89, while revenue reached $501.4 million and adjusted EBITDA $126.9 million, up 9.7% and 15.2% year over year, respectively (Financial Highlights).

MetricQ4 FY26Q4 FY25 / expectationRead
Revenue$501.4M$457.1M prior year+9.7% (Financial Highlights)
Adjusted EPS$2.09~$1.89 published consensusBeat (Adjusted Earnings)
Adjusted EBITDA$126.9M$110.2M prior year+15.2% (Adjusted EBITDA)
FY26 revenue$1,954.1M$1,930M-$1,945M prior guidanceAbove range (Fiscal Year 2027 Outlook / prior guidance)
FY26 adjusted EPS$8.25$7.95-$8.15 prior guidanceAbove range (Adjusted Earnings / prior guidance)
FY27 revenue growth5%-7%6%-8% long-term targetBelow target range (Fiscal Year 2027 Outlook)
FY27 adjusted EPS growth8%-11%9%-13% long-term targetBelow target range (Fiscal Year 2027 Outlook)

The full-year result also cleared the company’s own raised bar. FY26 revenue of $1.954 billion exceeded the prior $1.930-$1.945 billion guidance range, and adjusted EPS of $8.25 exceeded the prior $7.95-$8.15 range (Fiscal Year 2027 Outlook; Adjusted Earnings). That is genuine incremental information rather than merely a record result, because the company had already raised its targets in May.

Growth remains uneven across the portfolio. Walden was the clear engine, with enrollment up 14.0%, revenue up 16.1%, adjusted operating income up 30.6%, and adjusted EBITDA up 29.8% for FY26 (Segment Highlights — Walden). Medical and Veterinary also delivered healthy double-digit profit growth. By contrast, Chamberlain’s FY26 revenue rose only 3.4%, while adjusted operating income fell 6.3% and adjusted EBITDA declined 3.1%; enrollment growth recovered to just 1.6% (Segment Highlights — Chamberlain). The recovery is real, but the largest segment has not yet returned to prior profitability levels.

The main offset is a softer-than-promised starting point for the next strategy cycle. FY27 guidance calls for 5%-7% revenue growth and 8%-11% adjusted EPS growth (Fiscal Year 2027 Outlook), below the 6%-8% revenue and 9%-13% adjusted EPS growth targets previously outlined for FY27. The filing does not provide a new analyst consensus for FY27, so this is best read as a shortfall versus the company’s standing long-term framework, not a confirmed consensus miss.

Balance-sheet execution adds support to the beat. Covista repurchased $238 million of shares, repaid $50 million of Term Loan B debt, generated $393.1 million of free cash flow, and ended the year at 0.5x net leverage (Fiscal Year Capital Allocation; Free Cash Flow; Net Leverage). Those actions strengthen per-share results and financial flexibility, although the lower FY27 growth framework keeps the net read from being unequivocally strong.

Original filing on SEC EDGAR

More Covista Inc. news

Strong Q4 beat and FY26 outperformance, but FY27 targets reset lower | CVSA Stock News
AllSight

Breaking down Wall Street's
information edge.

A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.

—
8-K events this week
—
filings analyzed in total
live · updated 30s ago
Live events · whole market · · --:--:-- ET
AllSight read
Straight from the 8-K
Verbatim from the filing AllSight decoded — highlighted above. Open on SEC EDGAR ↗
Limited-time offerFree 14-day Pro trial
AllSight

Sign in to AllSight

  • Follow any company — we email you the moment it files, free!
  • Your watchlist saved to your account, on every device — free!

by Signing in NOW, claim your FREE 14-day Pro trial!

No password. We email you a 6-digit code. By continuing you agree to our Terms & Privacy.
AllSight · Live plain-English 8-K decodes across the whole US market · Not investment advice.